• 1 out of every 8 American women will develop breast cancer at some point in her life
• Breast cancer is the leading cause of cancer death among women ages 35 to 50
• 250,000 US women living with the disease are under the age of 40
• 8 out of 9 women who are diagnosed with breast cancer have no family history of the disease
• 70% of women who develop breast cancer have no identifiable risk factors

HALO Breast Pap Test is helping physicians shift their focus from diagnosing and treating breast cancer to risk assessment and prevention. HALO can help you fight breast cancer before you even have it.

HALO is a simple five-minute test that can help determine your risk of breast cancer years earlier than a mammogram. Simply put, it’s the quickest, easiest way to give your doctor a heads-up, and you a head start.

The HALO Breast Pap Test identifies abnormalities at the cellular level, years earlier than a mammogram can find a lump. That’s why doctors recommend that women, ages 25 and up, be tested annually with the HALO system. HALO does not replace regular mammograms and breast exams. Click here to see how it works. Click here to find a doctor in your area who offers HALO.

HALO is a new tool to help identify women at high risk for developing breast cancer in the future.  High risk women and their doctors can proactively take steps to reduce their risk and develop an individualized monitoring plan.

A cervical Pap test has become a routine part of your annual check-up because it identifies abnormal cell activity that could eventually become cancerous. Since the cervical Pap test was developed fifty years ago, statistics show that deaths from cervical cancer have decreased more than 80%, thanks largely to the Pap test. By comparison, only modest progress has been made in reducing the occurrence of breast cancer, and breast cancer statistics have stayed at an alarmingly high level.

.

Over the coming years, the HALO Breast Pap Test will become routine, too. Similar to the cervical Pap test, HALO identifies abnormal cells in breast fluid long before cancer might develop.

In clinical studies that followed over 20,000 women for up to 25 years, statistics revealed that women had a 4 to 5 times greater risk of developing breast cancer if abnormal cells were detected in their breast ducts. ^{1 2 3 4}

HALO can help you and your physician identify your risk for breast cancer, so that you can take a proactive approach to your breast health.

Test your knowledge

Click here for more information on the HALO Breast Pap Test
Click here to view the HALO Breast Pap Test patient video

Click here for HALO Breast Pap Test procedure details

¹ Hartmann LC, Sellers TA, Frost MA, et al. Benign Breast Disease and the Risk of Breast Cancer. NEJM 2005;353(3):229-237
² Wrensch MR, Petrakis NL, et al. Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. Am J Epidemiol 1992;135(2):130-141
³ Fabian CJ, Kimler BF. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail Risk Model. JNCI 2000; 92(15):1217-1227
⁴ Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. NEJM 1985;312(3):146-15